Findings represent major and essential step toward future human clinical trials
Led by researchers at University of California San Diego School of Medicine, a diverse team of neuroscientists and surgeons successfully grafted human neural progenitor cells into rhesus monkeys with spinal cord injuries. The grafts not only survived, but grew hundreds of thousands of human axons and synapses, resulting in improved forelimb function in the monkeys.
The findings, published online in the February 26 issue of Nature Medicine, represent a significant step in translating similar, earlier work in rodents closer to human clinical trials and a potential remedy for paralyzing spinal cord injuries in people.
“For more than three decades, spinal cord injury research has slowly moved toward the elusive goal of abundant, long-distance regeneration of injured axons, which is fundamental to any real restoration of physical function,” said Mark Tuszynski, MD, PhD, professor of neuroscience and director of the UC San Diego Translational Neuroscience Institute.
“While there was real progress in research using small animal models, there were also enormous uncertainties that we felt could only be addressed by progressing to models more like humans before we conduct trials with people,” Tuszynski said.
“We discovered, for example, that the grafting methods used with rodents didn’t work in larger, non-human primates. There were critical issues of scale, immunosuppression, timing and other features of methodology that had to be altered or invented. Had we attempted human transplantation without prior large animal testing, there would have been substantial risk of clinical trial failure, not because neural stem cells failed to reach their biological potential but because of things we did not know in terms of grafting and supporting the grafted cells.”
Gregoire Courtine, PhD, a professor and investigator at the Center for Neuroprosthetics and at the Brain Mind Institute, both part of the Swiss Federal Institute of Technology (EPFL) in Geneva, also conducts research seeking to restore function after spinal cord injury. He underscored the importance of the new findings.
“Dr. Tuszynski and his collaborators overcame a number of methodological difficulties specific to primates to obtain this breakthrough,” he said. “Direct translation of their work to humans would have failed, and yet too many studies are bypassing vital translational work in primate models that is necessary before human clinical trials.”
Successfully growing and proliferating functional grafted stem cells in spinal cord injuries is hindered by a multitude of innate, biological challenges. For example, the region surrounding the injury site — the so-called extracellular matrix — inhibits growth in the same way that a superficial scar never resembles the original tissue in form or function. The injury site is abundant with inhibitory myelin proteins (used to make the insulating sheath around many nerve fibers) but lacks growth-promoting factors, such as neurotrophins, that would encourage regeneration of nerve cells’ axons and synapses.
Previous work by Tuszynski and others have found solutions or work-arounds for many of these obstacles, reporting notable progress using rodent models. The new work involves the use of human spinal cord-derived neural progenitor cells (NPCs) — stem cells destined to become nerve cells in the central nervous system (CNS) — in rhesus monkeys, whose biology and physiology is much more similar to humans. Because the NPCs were derived from an 8-week-old human embryonic spinal cord, they possessed active growth programs that supported robust axon extension and appeared to be insensitive to inhibitors present in the adult CNS.
Two weeks after the initial injury (a period intended to represent the time required for an injured person to medically stabilize undergoing neural stem cell therapy), researchers grafted 20 million NPCs into the injury lesions in the monkeys, supported by a cocktail of growth factors and immune suppression drugs.
The work was done at the California National Primate Research Center at UC Davis. Most of the investigators are from UC campuses. “This highly complex translational project shows the value of collaborative research across UC campuses with unique facilities,” said co-author Michael Beattie, PhD, professor and director of research at the Brain and Spinal Injury Center at UC San Francisco.
Over the next nine months, the grafts grew, expressing key neural markers and sending hundreds of thousands of axons — the fibers through which nerve cells conduct signals to other nerve cells — through the injury site to undamaged cells and tissue on the other side. Several months into the study, researchers noted that the monkeys began to display partial recovery of movement in their affected forelimbs.
Notably, the team documented regeneration of corticospinal axons, which are essential for voluntary movement in humans, into the lesion sites — the first such known documentation in a primate model.
Courtine at EPFL, who was not involved in the study, said the findings challenge decades of work on the mechanisms of regeneration failure and “definitely represent a landmark in regeneration medicine.” Nonetheless, he noted that the degree of functional improvement remained limited. “It is not surprising given that the functional integration of new cells and connections into the operation of the nervous system would require time and specific rehabilitation procedures,” he said.
“It’s possible that given a longer period of observation, greater recovery may have occurred,” said the study’s first author, Ephron S. Rosenzweig, PhD, an assistant adjunct professor in Tuszynski’s lab. “Axon regeneration, synapse formation, myelination — these all take time, and are critical for neural function. Grafts, and the new circuitry they were part of, were still maturing at the end of our observations, so it seems possible that recovery might have continued.”
Tuszynski said work remains to be done before initiating human clinical trials, including production of a candidate neural stem cell line from humans that meets requirements of the Food and Drug Administration, and additional studies of safety. His group also continues to explore ways to further enhance the growth, distance and functionality of the regenerated cells.
“We seem to have overcome some major barriers, including the inhibitory nature of adult myelin against axon growth,” he said. “Our work has taught us that stem cells will take a long time to mature after transplantation to an injury site, and that patience will be required when moving to humans. Still, the growth we observe from these cells is remarkable — and unlike anything I thought possible even ten years ago. There is clearly significant potential here that we hope will benefit humans with spinal cord injury.”
The Latest on: Spinal cord injuries
- Electrical stimulation technique helps patients with spinal cord injury on February 20, 2019 at 9:46 am
This article was originally published on The Conversation, an independent and nonprofit source of news, analysis and commentary from academic experts. Disclosure information is available on the ... […]
- Can a nerve injury trigger ALS? on February 20, 2019 at 8:24 am
"Our results show that a single nerve injury, which is small enough that it only causes temporary weakness in normal animals, can start a cascade of inflammation in the spinal cord that initiates ... […]
- Japan approves world-first trial using iPS cells to treat spinal cord injuries on February 19, 2019 at 6:17 pm
The health ministry on Monday approved the world’s first clinical test in which artificially derived stem cells will be used to treat patients with spinal cord injuries. A team of researchers from Kei... […]
- Kennedy Krieger Institute Provides Hope For Spinal Cord Patients With Ski Trip on February 19, 2019 at 3:07 pm
BALTIMORE (WJZ) — The Kennedy Krieger Institute is providing hope for patients with spinal cord injuries, through new experiences and activities. In January, Van Brooks skied for the first time. […]
- The Ted Thompson-era Packers lost several key draft picks far too early to injury on February 19, 2019 at 11:38 am
Carted off the field with a spinal cord injury, the Packers faithful never again saw the blossoming playmaker catch passes from Aaron Rodgers. Unlike some other notable draft picks in the Ted Thompson ... […]
- Spinal Cord Injury Could Throw Off Body’s Internal Clock on February 19, 2019 at 6:41 am
Although paralysis is the most noticeable result of a spinal cord injury, a new study by researchers at The University of Texas (UT) at Austin suggests such injuries could throw off the internal clock ... […]
- Ministry OKs 1st iPS cell therapy trial for spinal cord injuries on February 19, 2019 at 2:00 am
The health ministry gave the go-ahead Feb. 18 for the world’s first clinical trial of human induced pluripotent stem (iPS) cells to treat spinal cord injuries, raising hopes for those with the chronic ... […]
- Japan trial to treat spinal cord injuries with stem cells on February 18, 2019 at 8:30 am
A team of Japanese researchers will carry out an unprecedented trial using a kind of stem cell to try to treat debilitating spinal cord injuries. (Shutterstock/Elena Pavlovich) A team of Japanese rese... […]
- Japan approves test of iPS cells for treating spinal injuries on February 18, 2019 at 12:54 am
TOKYO (Reuters) - Japanese scientists will test the use of human-induced pluripotent stem cells (iPS) to treat spinal cord injuries, a health ministry panel that approved the research project said on ... […]
- Spinal cord stimulator device shows promise in Minneapolis study on February 16, 2019 at 5:00 am
Two middle-aged women who were paralyzed from spinal injuries at least five years ago can move their legs again after having the Abbott device implanted to deliver epidural spinal cord stimulation, th... […]
via Google News and Bing News